Ménière's disease (MD) is a chronic inner ear syndrome characterized by vertigo, tinnitus, and fluctuating sensorineural hearing loss. Despite its well-defined clinical presentation, the underlying pathophysiology remains elusive, often resulting in empirical and partially effective treatments....
Preliminary metabolomics findings suggest Ménière's disease has systemic metabolic involvement, but this is exploratory science — no actionable change for clinical practice at this stage.
Identifying systemic metabolic signatures in Ménière's disease could open pathways for biomarker-based diagnosis and novel therapeutic targets beyond endolymphatic hydrops management.
- 01Urinary 1H NMR metabolomics reveals systemic metabolic alterations specific to Ménière's disease.
- 02Findings suggest Ménière's is not purely a localised inner-ear disorder but has whole-body metabolic components.
- 03Metabolomics approach is exploratory; no diagnostic biomarker has been validated for clinical use.
- 04Results may inform future research into Ménière's aetiology and potential systemic treatments.
- 05Study population and sample size not specified in the abstract.
Patients with Ménière's disease exhibit systemic metabolic alterations detectable in urine via NMR-based metabolomics.
studypartially supportedMénière's disease involves systemic metabolic dysregulation beyond inner-ear pathology.
studyunclear- PMID
- 42111213
- DOI
- 10.1016/j.isci.2026.115826.
- Journal
- iScience
- Publication type
- research_article
- Evidence level
- 4
- Population
- Patients with Ménière's disease
- Intervention
- Urinary 1H NMR-based metabolomics profiling
Primary outcomes
Identification of systemic metabolic alterations in Ménière's disease patients via urinary metabolomics